MADRID, 28 Sep. (CNMV) -
Almirall announces positive phase III results showing efficacy of LAS41008 (dimethyl fumarate), a new systemic oral drug for patients with chronic plaque psoriasis
Información completa en:
http://www.cnmv.es/portal/hr/HRAlDia.aspx?lang=es .
